Skip to main content

COVID-19 Topic Center

Ankylosing Spondylitis News

News
In a double-blind, Phase 3 trial of adults with active ankylosing spondylitis who had an inadequate response to at least two nonsteroidal anti-inflammatory drugs (NSAIDS), the oral Janus kinase inhibitor tofacitinib demonstrated significantly greater efficacy than placebo. Researchers published…
News
Golimumab was effective and showed a high probability of treatment persistence up to 4 years as a second anti-tumor necrosis factor (anti-TNF) drug in patients with spondyloarthritis who needed to discontinue their first anti-TNF drug for reasons other than primary nonresponse, according to a study…
News
Among the 17.8% of patients with ankylosing spondylitis who had their initial tumor necrosis factor inhibitor (TNFi) dose reduced over 2 years, medical costs dropped significantly, according to a study published online ahead of print in the journal Rheumatology and Therapy.  “TNFis may be…
News
No biologic strategies in treatment guidelines for ankylosing spondylitis were cost-effective at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year (QALY), according to a study published in the Journal of Managed Care & Specialty Pharmacy.  “Nevertheless,” researchers…
News
Patients with ankylosing spondylitis who switch or discontinue their biologic within a year of starting it have higher health care utilization and medical costs compared with patients who stay with their index biologic, according to a study published online in the Journal of Managed Care &…
News
Both the introduction and switching of biologic disease modifying anti-rheumatic drugs (bDMARDs) were associated with the use of depression and anxiety medications in a real-world population of patients with inflammatory rheumatic diseases. Researchers published their findings online in RMD Open…
News
Patients with axial spondyloarthritis who experienced higher levels of perceived stress and anxiety during the current shelter-in-place orders had significantly higher disease activity levels compared with patients with less stress and anxiety, according to a study published online in ACR Open…
News
Patients with ankylosing spondylitis showed sustained improvement in signs, symptoms, and physical function after 5 years of treatment with subcutaneous secukinumab 150 mg, according to results from a phase 3 trial published online in The Lancet Rheumatology. “Secukinumab, a fully human monoclonal…
News
Patients with inflammatory arthritis who switched from a first-line to a second-line subcutaneous tumor necrosis factor alpha inhibitor (SC-TNFi) incurred significantly higher nontreatment health care resource utilization (HCRU) costs 12 months after the switch. Patients who stayed with their first…
News
By Anne Harding NEW YORK (Reuters Health) - Patients with ankylosing spondylitis (AS) who start taking statins live longer than those who aren’t on the cholesterol-lowering drugs, according to a new population-based cohort study. “The study suggests that statins could be potentially a good…
Back to Top